A trailblazing pioneer, Affymetrix (NASDAQ:AFFX) got off largely under-the-radar in 1992, and came public with its IPO in June 1996.
AFFX "blasted-off" like a rocket in the early 2000s (with over a 1500% Total Return), as it developed its DNA Chip Technology ("biochips") and integrated products, and was on the leading edge in preparing and positioning itself for The Human Genome Project, the worldwide project that completed sequencing the human gene and DNA (deoxyribonucleic acid). This led to the ongoing boom in biotechnology, big-pharma inroads, and R&D generally, and advancements in learning, as well as exponential leaps in medicine have continuously been made.
Having been professionally engaged in a career in the medicine/ healthcare field most of my...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|